SAN FRANCISCO, June 28, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its participation in the following upcoming investor conferences:
- Piper Jaffray GenomeRx Symposium
Panel: Gene Therapy – Tackling Manufacturing
July 11, 2017, 11:20 am ET
The Lotte New York Palace, New York
- Wedbush PacGrow Healthcare Conference
August 15, 2017, 12:45 pm ET
Le Parker Meridien Hotel, New York
To access a live webcast of the corporate presentation at the Wedbush PacGrow Healthcare Conference, please visit the Events & Presentations page within the Investors & News section of the Audentes website. A replay of the live webcast will be available on the Audentes website for approximately 30 days following the conference. There is no webcast available for the Gene Therapy – Tackling Manufacturing panel at the Piper Jaffray GenomeRx Symposium.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.
For more information regarding Audentes, please visit www.audentestx.com.
Thomas Soloway, CFO
SOURCE Audentes Therapeutics, Inc.